JP2007535930A5 - - Google Patents

Download PDF

Info

Publication number
JP2007535930A5
JP2007535930A5 JP2007511437A JP2007511437A JP2007535930A5 JP 2007535930 A5 JP2007535930 A5 JP 2007535930A5 JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007511437 A JP2007511437 A JP 2007511437A JP 2007535930 A5 JP2007535930 A5 JP 2007535930A5
Authority
JP
Japan
Prior art keywords
skin
subject
expression
antagonist
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014720 external-priority patent/WO2005108616A1/en
Publication of JP2007535930A publication Critical patent/JP2007535930A/ja
Publication of JP2007535930A5 publication Critical patent/JP2007535930A5/ja
Pending legal-status Critical Current

Links

JP2007511437A 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法 Pending JP2007535930A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56774704P 2004-05-03 2004-05-03
PCT/US2005/014720 WO2005108616A1 (en) 2004-05-03 2005-05-02 Use of il-17 expression to predict skin inflammation; methods of treatment

Publications (2)

Publication Number Publication Date
JP2007535930A JP2007535930A (ja) 2007-12-13
JP2007535930A5 true JP2007535930A5 (https=) 2008-06-19

Family

ID=34967584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007511437A Pending JP2007535930A (ja) 2004-05-03 2005-05-02 皮膚の炎症を予測するためのｉｌ−１７発現の使用；処置方法

Country Status (11)

Country Link
US (2) US7501247B2 (https=)
EP (1) EP1761643A1 (https=)
JP (1) JP2007535930A (https=)
CN (1) CN1993480A (https=)
AU (1) AU2005241020B2 (https=)
BR (1) BRPI0510617A (https=)
CA (1) CA2565566A1 (https=)
MX (1) MXPA06012754A (https=)
NO (1) NO20065560L (https=)
WO (1) WO2005108616A1 (https=)
ZA (1) ZA200609140B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
CN101052726A (zh) * 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
CN101160528A (zh) * 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
US20080199460A1 (en) * 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2007149814A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
EP2046835B1 (en) 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN102449170A (zh) * 2009-04-15 2012-05-09 西北大学 寡核苷酸功能化的纳米颗粒的递送
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2493506B1 (en) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a antagonists
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
US20140235475A1 (en) * 2011-06-27 2014-08-21 Isabelle Carlavan Th17 differentiation markers for acne and uses thereof
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
WO2019217478A1 (en) 2018-05-09 2019-11-14 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EA201792527A1 (ru) * 2015-07-16 2018-06-29 Эли Лилли Энд Компани Лечение зуда
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CA3090785A1 (en) 2018-02-14 2019-08-22 John Daniel Dobak Iii Novel gene classifiers and uses thereof in non-melanoma skin cancers
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
ES2380812T3 (es) 1999-12-23 2012-05-18 Genentech, Inc. Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
US6756481B2 (en) * 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
EP2366406A1 (en) * 2001-01-25 2011-09-21 ZymoGenetics, Inc. Method for treating psoriasis
US20020169127A1 (en) 2001-03-29 2002-11-14 Charmley Patrick R. Compositions and methods for diagnosing or treating psoriasis
WO2004042009A2 (en) * 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004058178A2 (en) * 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
AU2003301114B2 (en) 2002-12-31 2010-03-18 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
CN101052726A (zh) * 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment

Similar Documents

Publication Publication Date Title
JP2007535930A5 (https=)
Greenberg et al. Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children
Parikh et al. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis
Eardley et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease
Michael et al. Epidemiology of anxiety disorders
US20220252617A1 (en) Biomarkers of fast progression of chronic kidney disease
Hwang et al. Tissue expression of tubular injury markers is associated with renal function decline in diabetic nephropathy
JP2013231045A5 (https=)
Zhou et al. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy
Kim et al. Non-eosinophilic nasal polyps shows increased epithelial proliferation and localized disease pattern in the early stage
JP2013500940A5 (https=)
Iwasa et al. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study
Genovese et al. Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients
Shima et al. Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy
BR112012007365A2 (pt) proteínas de ligação à il-1
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
Choi et al. Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients
BR112013027867A2 (pt) "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
Fu et al. Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus
Oh et al. Circulating tumor necrosis factor α receptors predict the outcomes of human IgA nephropathy: a prospective cohort study
Youssry et al. Novel marker for the detection of sickle cell nephropathy: soluble FMS-like tyrosine kinase-1 (sFLT-1)
Yin et al. C-reactive protein: rethinking its role in evaluating the severity of hyperlipidemic acute pancreatitis
Lacquaniti et al. Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin
Dey et al. Lymphocytic colitis is associated with increased pro-inflammatory cytokine profile and up regulation of prostaglandin receptor EP4
Rotstein Circulating cytokines in predicting development of severe acute pancreatitis